Evolus, Inc. cotiza a 7.75 USD y tiene una capitalización bursátil de $512M. En los últimos 12 meses ha facturado $316M con un margen de flujo de caja libre del -15.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.02 | $-0.05 | $0.01 |
| Estimado | $-0.07 | $-0.04 | $-0.12 | $0.04 |
| Sorpresa | — | +50.0% | +58.3% | -75.0% |
| Métrica | EOLS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 66.3% | 57.0% | +9.3% |
| Operating Margin | -11.0% | -38.6% | +27.6% |
| Net Margin | -17.4% | -33.6% | +16.2% |
| FCF Margin | -15.4% | -13.9% | -1.5% |
| ROE | — | -40.4% | — |
| ROA | -22.9% | -32.0% | +9.1% |
| Current Ratio | 1.90 | 2.84 | -0.94 |
| Debt / Equity | -6.32 | 0.28 | -6.60 |